Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with BronchiectasisPRNewsWire • 05/28/24
Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with BronchiectasisPRNewsWire • 05/27/24
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International ConfePRNewsWire • 05/20/24
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline UpdatesZacks Investment Research • 05/10/24
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/09/24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 05/09/24
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/24
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024PRNewsWire • 04/25/24
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International ConferencePRNewsWire • 03/27/24
Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their HealthPRNewsWire • 02/28/24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business UpdatePRNewsWire • 02/22/24
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024PRNewsWire • 02/08/24
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/24